Physician profile
Sammy A Hutman
NPI 1881692481
$3,716.82
in general payments reported to CMS, 2019-2025
26 companies · $850 in 2025
The $850 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $207 · 2020: $25.14 · 2021: $112 · 2022: $224 · 2023: $1,168 · 2024: $1,131 · 2025: $850.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,119 · Education: $30.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,118.62 |
| Education | $30.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $788.17 | 2021-2025 | Opzelura, Opzelura |
| Janssen Biotech, INC. | $672.98 | 2019-2025 | Tremfya, Stelara, Simponi |
| Sun Pharmaceutical Industries INC. | $478.59 | 2019-2025 | Absorica Ld, Winlevi |
| Genzyme Corporation | $273.54 | 2023-2024 | |
| Abbvie INC. | $256.70 | 2019-2025 | |
| Lilly USA, LLC | $229.38 | 2019-2025 | Ebglyss, Taltz, Olumiant |
| Verrica Pharmaceuticals INC. | $139.04 | 2023 | Ycanth |
| Pfizer INC. | $129.29 | 2019-2024 | |
| Galderma Laboratories, L.P. | $101.19 | 2019-2025 | Nemluvio |
| Sandoz INC. | $85.45 | 2019-2021 | |
| Arcutis Biotherapeutics, INC. | $76.64 | 2023-2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $58.87 | 2022-2024 | Sotyktu |
| Amgen INC. | $57.77 | 2022-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $53.92 | 2022-2024 | |
| Dermavant Sciences, INC. | $49.34 | 2024 | Vtama |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $47.53 | 2019-2025 | Cabtreo, Jublia, Siliq |
| Biofrontera INC. | $36.58 | 2019-2021 | |
| Promius Pharma LLC | $25.09 | 2019 | |
| Botanix Sb INC | $24.00 | 2025 | Sofdra |
| Journey Medical Corporation | $22.63 | 2025 | |
| Almirall LLC | $21.46 | 2023 | Seysara |
| Regeneron Healthcare Solutions, INC. | $21.05 | 2024 | Dupixent |
| Ucb, INC. | $20.96 | 2024 | Bimzelx |
| Helsinn Therapeutics (U.S.), INC. | $20.13 | 2023 | Valchlor |
| Leo Pharma INC. | $15.90 | 2021 | |
| Organon LLC | $10.62 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sammy Hutman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.